Respiratory
syncytial virus (RSV) stands as the foremost
cause
of infant hospitalization globally, ranking second only to malaria
in terms of infant mortality. Although three vaccines have recently
been approved for the prophylaxis of adults aged 60 and above, and
pregnant women, there is currently no effective antiviral drug for
treating RSV infections. The only preventive measure for infants at
high risk of severe RSV disease is passive immunization through monoclonal
antibodies. This Perspective offers an overview of the latest advancements
in RSV drug discovery of small molecule antivirals, with particular
focus on the promising findings from agents targeting the fusion and
polymerase proteins. A comprehensive reflection on the current state
of RSV research is also given, drawing inspiration from the lessons
gleaned from HCV and HIV, while also considering the impact of the
recent approval of the three vaccines.